[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.197.114. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
October 3, 2001

Congestive Heart Failure Treatment

Author Affiliations
 

Not Available

Not Available

JAMA. 2001;286(13):1569. doi:10.1001/jama.286.13.1569-JFD10009-2-1

The FDA has approved nesiritide (Natrecor; Scios Inc, Sunnyvale, Calif) for initial intravenous treatment of patients with acutely decompensated congestive heart failure (ADCHF). The drug is a sterile, purified preparation containing the human B-type natriuretic peptide.

Nesiritide has been studied in 10 trials of patients with CHF, including the randomized Vasodilation in the Management of Acute Congestive Heart Failure (VMAC) trial, which enrolled 489 patients requiring hospitalization for management of ADCHF with shortness of breath at rest.

First Page Preview View Large
First page PDF preview
First page PDF preview
×